Shares of Antares Pharma Inc (NASDAQ:ATRS) have been assigned a consensus rating of “Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $4.83.
A number of equities research analysts have weighed in on the stock. BidaskClub upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, July 3rd. HC Wainwright reiterated a “buy” rating and set a $4.50 target price on shares of Antares Pharma in a research note on Monday, May 6th.
Shares of ATRS stock traded down $0.02 during trading hours on Thursday, hitting $3.35. 13,271 shares of the company’s stock traded hands, compared to its average volume of 1,654,581. The stock has a fifty day moving average price of $3.00. Antares Pharma has a 12-month low of $2.53 and a 12-month high of $3.96. The firm has a market cap of $546.40 million, a PE ratio of -84.00 and a beta of 1.03. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.90 and a current ratio of 2.28.
In other news, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $2.67, for a total transaction of $80,100.00. Following the completion of the sale, the director now owns 190,213 shares of the company’s stock, valued at approximately $507,868.71. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.49% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of ATRS. BlackRock Inc. raised its holdings in Antares Pharma by 3.1% during the 4th quarter. BlackRock Inc. now owns 10,234,202 shares of the specialty pharmaceutical company’s stock worth $27,839,000 after buying an additional 304,945 shares during the period. Cortina Asset Management LLC grew its stake in Antares Pharma by 100.3% during the 2nd quarter. Cortina Asset Management LLC now owns 2,072,605 shares of the specialty pharmaceutical company’s stock valued at $6,819,000 after acquiring an additional 1,037,675 shares in the last quarter. Northern Trust Corp grew its stake in Antares Pharma by 0.4% during the 4th quarter. Northern Trust Corp now owns 1,741,602 shares of the specialty pharmaceutical company’s stock valued at $4,738,000 after acquiring an additional 6,868 shares in the last quarter. Geode Capital Management LLC grew its stake in Antares Pharma by 11.6% during the 4th quarter. Geode Capital Management LLC now owns 1,609,722 shares of the specialty pharmaceutical company’s stock valued at $4,378,000 after acquiring an additional 167,695 shares in the last quarter. Finally, Millennium Management LLC grew its stake in Antares Pharma by 118.2% during the 4th quarter. Millennium Management LLC now owns 1,507,964 shares of the specialty pharmaceutical company’s stock valued at $4,102,000 after acquiring an additional 816,798 shares in the last quarter. 42.36% of the stock is owned by institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Article: What is a management fee?
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.